Characterization and Application of a Nose-Only Exposure Chamber for Inhalation Delivery of Liposomal Drugs and Nucleic Acids to Mice

Abstract

Background: A small nose-only exposure chamber was evaluated for inhalation delivery of drug carrier systems (DCSs) to mice for the treatment of lung cancer. The chamber then was used for inhalation delivery of an anticancer drug, antisense oligonucleotides (ASO), and small interfering RNA (siRNA) directly to the cancerous lungs of mice. Methods: The uniformity of particle delivery across the ports of the exposure chamber and stability of the DCS (liposomes) during continuous aerosolization by a Collison nebulizer were examined. The mean produced particle size by number was approximately 130 nm, and the mass median diameter was approximately 270 nm. The system was then used to deliver DCS containing doxorubicin (DOX) and ASO or siRNA targeted to multidrug resistance-associated protein 1 (MRP1) mRNA as suppressors of cancer cell resistance. The retention of the drug in the lungs and the effect on tumor size were compared after inhalation delivery and intravenous injection in a nu/nu mouse model of lung cancer. Results: The aerosol mass across the four inhalation ports had a coefficient of variation of less than 12%, and approximately 1.4% of the nebulized mass was available for inhalation at each port. The mean size of 130 nm of liposomal DCS did not change significantly during continuous 60-min aerosolization. For inhalation delivery of DCS with DOX + ASO/siRNA, the amount of drugs available for inhalation was lower compared with intravenous injection of DOX; however, the observed lung dose and the retention time were significantly higher. The delivery of DOX + ASO/siRNA via inhalation resulted in tumor volume reduction of more than 90%, whereas only about 40% reduction was achieved after intravenous injection of DOX. Conclusions: The investigated exposure system is suitable for inhalation delivery of complex DCS, and its use to deliver DCS containing anticancer drugs and resistance suppressors via inhalation offered a superior method for lung cancer treatment in mice compared with intravenous injections.

Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment

“…The complete dual-action nanodrug on the PMLA nanoplatform with covalently attached AONs targeting EGFR and angiogenic laminin-411, combined with TfR mAbs for extravasation and targeted tumor uptake, was readily synthesized and administrated systemically. AON as anti-cancer drugs have been successfully used to treat experimental tumors [48,49]. In particular, Morpholino AONs used in our work are stable in circulation and are being increasingly used in gene therapy [50,51].…”

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment

“…Advantages to aerosol administration of medications to the lung include a high local concentration by delivery directly to the airways, a reduced distribution to systemic circulation and, for drugs that would otherwise require subcutaneous or intravenous injection, pain-and needle-free delivery. Several therapeutic agents have been explored for inhalation delivery in malignancies, including chemotherapeutic agents, 20,21 cytokines, 22,23 antisense oligonucleotides 24 and monoclonal antibodies, 25 demonstrating the feasibility of aerosol delivery, potential antitumor effects and reduced side-effects compared to systemic treatment.…”

siRNA Delivery to the lung: What's new?

“…installation of luciferase expressing A549 cells. The tumor progression was followed as described before [80], and the particles were administered by nose-only inhalation or by i.v. injection.…”